Literature DB >> 1734325

Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration.

A J Thompson1, D Miller, B Youl, D MacManus, S Moore, D Kingsley, B Kendall, A Feinstein, W I McDonald.   

Abstract

In the planning of MRI protocols to monitor disease activity in multiple sclerosis (MS), the clinical subtype needs to be considered. In this serial gadolinium-enhanced MRI study, we demonstrated differences between patients with early relapsing/remitting MS and benign MS in both the production of new lesions and the occurrence of enhancement.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1734325     DOI： 10.1212/wnl.42.1.60

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  28 in total

1.  Neutralizing antibodies against interferon-Beta.

Authors:  Per Soelberg Sorensen
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

2.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

3.  Central inflammation versus peripheral regulation in multiple sclerosis.

Authors:  L J Edwards; B Sharrack; A Ismail; H Tumani; C S Constantinescu
Journal:  J Neurol       Date:  2011-03-09       Impact factor: 4.849

Review 4.  Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

Authors:  J H Simon
Journal:  West J Med       Date:  1996-06

5.  Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.

Authors:  N Tubridy; H J Ader; F Barkhof; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

Review 6.  Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment.

Authors:  M Filippi; M Rovaris; G Comi
Journal:  Ital J Neurol Sci       Date:  1996-12

7.  Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis.

Authors:  M Filippi; R Capra; A Campi; B Colombo; F Prandini; N Marcianò; R Gasparotti; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

8.  Database for serial magnetic resonance imaging in multiple sclerosis.

Authors:  F Barkhof; A J Thompson; L Kappos; J J Nauta; T Yousri; I Berry; G Scotti; B Appel; P S Tofts; D H Miller
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

9.  Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity.

Authors:  D Kidd; A J Thompson; B E Kendall; D H Miller; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

10.  A spinal cord MRI study of benign and secondary progressive multiple sclerosis.

Authors:  M Filippi; A Campi; B Colombo; C Pereira; V Martinelli; C Baratti; G Comi
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.